257: Lilly’s Alzheimer’s success, a milestone FDA approval, & Moderna’s shrinking business скачать в хорошем качестве

257: Lilly’s Alzheimer’s success, a milestone FDA approval, & Moderna’s shrinking business

What’s the future of Alzheimer’s disease treatment? How do you pivot from a pandemic? And how successful can Wegovy get? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Eli Lilly’s investigational medicine for Alzheimer’s met its goals in an all-important clinical trial, and we explain the results, their implications, and the backstory of what could be a blockbuster drug. We also discuss the latest news in the life sciences, including a busy week of earnings, a long-awaited FDA approval, and the highlights from STAT’s Breakthrough Summit in San Francisco. More from STAT: Become a subscriber: https://www.statnews.com/stat-plus/ Watch Full Episodes: / @statnews Newsletters: https://www.statnews.com/signup/ STAT events: https://www.statnews.com/stat-events/ Facebook:   / statnews   Twitter:   / statnews   Instagram:   / statnews   Flipboard: rb.gy/3xnsxr STAT Reports: https://rb.gy/rexfwj STAT eBooks: https://rb.gy/eme3h5 ABOUT STAT: Founded in 2015, STAT is a global digital media brand that focuses on delivering fast, deep, and tough-minded journalism about the life sciences industries to over six million monthly site visitors and an additional 20 million readers on the Apple News app. STAT takes you inside academic labs, biotech boardrooms, and political backrooms, casting a critical eye on scientific discoveries, scrutinizing corporate strategies, and chronicling the roiling battles for talent, money, and market share. With an award-winning newsroom, STAT provides indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life sciences industry — and a revolution in human health.